New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
09:03 EDTBAYRY, ONXXBayer and Onyx Pharmaceuticals say sorafenib trial did not meet primary endpoint
Bayer (BAYRY) and Onyx Pharmaceuticals (ONXX) said a Phase III Trial of sorafenib, an adjuvant therapy for a form of liver cancer, did not meet primary endpoint. "We are disappointed that the trial did not meet its primary endpoint. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer," said the Bayer HealthCare Executive Committee.
News For BAYRY;ONXX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
15:40 EDTBAYRYPanasonic Healthcare may bid for Bayer's blood glucose meter unit, Nikkei says
Subscribe for More Information
March 26, 2015
11:13 EDTBAYRYBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:04 EDTBAYRYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
05:31 EDTBAYRYBayer downgraded to Neutral from Buy at UBS
Subscribe for More Information
March 25, 2015
07:17 EDTBAYRYSociety for Reproductive Investigation to hold scientific meeting
62nd Annual Scientific Meeting: SRI 2015 is being held in San Francisco on March 25-28.
March 20, 2015
07:41 EDTBAYRYAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use